8-K: Propanc Biopharma Secures $25,000 Convertible Note and Short-Term Loan Amidst Challenging Terms

Propanc Biopharma, Inc. has entered into a $25,000 convertible redeemable note with GEEBIS CONSULTING, LLC and a short-term AU$13,188 loan with a Board Member to fund general working capital.

Summary

• Propanc Biopharma, Inc. secured an 8% Convertible Redeemable Note with a principal amount of US $25,000.00 from GEEBIS CONSULTING, LLC, maturing on June 12, 2026.
• The Note was acquired for a purchase price of US $22,500.00, reflecting a US $2,500.00 original issue discount.
• Interest on the Note, commencing June 12, 2025, is 8% per annum and is payable in Common Stock (Interest Shares).
• The Note is convertible into common stock at a fixed price of $5.00 per share, which can adjust to $3.00 per share if the Common Stock trades below $4.00 for more than five consecutive trading days.
• In an Event of Default, the conversion price for the Note becomes 65% of the lowest trading price of the Common Stock over the ten prior trading days.
• The Company has the right to prepay the Note within the first 180 days, subject to premiums ranging from 110% to 125% of the principal plus accrued interest, with no prepayment right after 180 days.
• The Company also entered into a short-term loan agreement for AU$13,188.00 with Aggro Investments Pty Ltd, an entity associated with a Board Member, bearing a 12% annual interest rate and due on June 30, 2025.
• Both financing arrangements are explicitly stated to be for general working capital purposes.

Sentiment

Score: 3

Explanation: The sentiment is generally negative. While the company secured capital, the terms of the convertible note (significant discount, high interest, highly dilutive conversion features, punitive default clauses) and the very short-term, high-interest related-party loan suggest financial distress and a high cost of capital. This indicates a challenging financial position and potential for significant future dilution for existing shareholders.

Positives

• The company successfully secured additional capital, totaling US $22,500 (net from the note) and AU$13,188, which is designated for general working capital purposes.
• The convertible note provides a mechanism for the company to manage its debt obligations, potentially through equity conversion rather than immediate cash repayment.

Negatives

• The convertible note includes a significant original issue discount of $2,500 on a $25,000 principal, effectively increasing the cost of capital.
• The interest rates are high: 8% per annum for the convertible note and 12% per annum (18% default rate) for the short-term loan, indicating potentially challenging financing conditions.
• The conversion terms of the note are highly dilutive, especially the provision for the conversion price to drop to $3.00 or 65% of the lowest trading price upon default, which could significantly increase the number of shares issued.
• The short-term loan from a Board Member has a very short maturity date (June 30, 2025), suggesting immediate and potentially urgent liquidity needs.
• The company faces substantial penalties for various events of default, including daily fines for failure to deliver shares ($250-$500 per day) and a 20% increase in outstanding principal for loss of bid price.
• The requirement to reserve 4x the amount of shares for full conversion of the note indicates a significant potential for future dilution.

Risks

• Dilution Risk: The variable conversion price of the note, particularly under default conditions or sustained low trading, poses a significant risk of substantial dilution to existing shareholders.
• Liquidity Risk: The very short maturity of the AU$13,188 loan (due June 30, 2025) suggests potential immediate liquidity challenges and reliance on short-term funding.
• High Cost of Capital: The combination of the original issue discount, high interest rates (8% and 12%), and prepayment premiums indicates that the company is incurring a high cost to secure necessary capital.
• Default Risk: The document outlines numerous events of default, including failure to pay, breach of covenants, failure to deliver shares, delisting, and delinquent SEC filings, which could trigger immediate repayment or severe penalties.
• Regulatory Compliance Risk: Failure to maintain listing on OTC Markets or other exchanges, or to comply with SEC reporting requirements, could lead to an event of default and associated penalties.
• Share Price Volatility Risk: The conversion price's linkage to the company's trading price means that further declines in share value could exacerbate dilution.

Future Outlook

The document states that the net proceeds from both the convertible note and the short-term loan are intended for general working capital purposes. No specific forward-looking statements regarding future financial performance, strategic initiatives, or operational guidance are provided beyond this financing.

Management Comments

• "The Company intends to use the net proceeds therefrom for general working capital purposes." (Regarding the convertible note)
• "The Company intends to use the net proceeds from the Loan for general working capital purposes." (Regarding the short-term loan)
• "The Company understands and acknowledges the potentially dilutive effect to the Common Stock upon the issuance of the Conversion Shares upon conversion of the Note."
• "The Company further acknowledges that its obligation to issue Conversion Shares upon conversion of the Note in accordance with this Agreement and the Note is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company."

Industry Context

This filing details a specific financing event for Propanc Biopharma, Inc. While the document does not provide explicit industry context, securing capital through convertible debt and short-term loans, especially with high interest rates and dilutive terms, is a common practice for smaller biopharma companies, particularly those in early development stages or facing liquidity constraints, as they may have limited access to more traditional or favorable financing options.

Comparison to Industry Standards

• The terms of the convertible note, including the 8% interest rate, original issue discount, and highly dilutive conversion features (especially upon default), appear to be less favorable than those typically secured by more established or financially robust companies in the biopharma sector.
• The very short-term, high-interest loan from a Board Member (AU$13,188 at 12% due in 17 days) is highly unusual for a publicly traded company and suggests an urgent, immediate need for liquidity that could not be met through conventional means or on more favorable terms.
• While specific comparable companies or projects are not mentioned in the document, the overall financing structure indicates that Propanc Biopharma may be facing significant challenges in attracting capital on terms indicative of strong financial health or promising near-term prospects, contrasting with companies that can secure non-dilutive or lower-cost debt/equity.

Related Party Transactions

• The Company entered into a loan agreement for AU$13,188.00 with Aggro Investments Pty Ltd, an entity associated with Mr. Josef Zelinger, a member of the Board of Directors.

Stakeholder Impact

• Shareholders: Face significant potential for dilution due to the convertible note's terms, especially if the stock price declines or events of default occur. The high cost of capital could also negatively impact future profitability and shareholder value.
• Creditors: The new debt instruments add to the company's financial obligations, increasing its leverage.
• Employees/Customers/Suppliers: The capital raise for working capital could help ensure continued operations and meet short-term obligations, but the challenging financing terms might signal underlying financial instability.

Next Steps

• The Company is obligated to maintain an initial reserve of at least 25,000 shares of Common Stock for conversions under the Note, and at all times reserve 4x the amount of shares required if the Note were fully converted.
• The Company must promptly secure and maintain the listing of the Conversion Shares upon each national securities exchange or automated quotation system where Common Stock is listed.
• The Company must comply in all respects with its reporting, filing, and other obligations under FINRA and applicable exchanges.
• The AU$13,188 loan from Aggro Investments Pty Ltd is due for repayment by June 30, 2025.

Key Dates

Recommendation

Keywords

Propanc Biopharma, Convertible Note, Debt Financing, Working Capital, SEC Filing, 8-K, Securities Purchase Agreement, Loan Agreement, Dilution, Corporate Finance, OTC Markets, Capital Raise